Double-input compartmental modeling and spectral analysis for the quantification of positron emission tomography data in oncology

In positron emission tomography (PET) studies involving organs different from the brain, ignoring the metabolite contribution to the tissue time-activity curves (TAC), as in the standard single-input (SI) models, may compromise the accuracy of the estimated parameters. We employed here double-input (DI) compartmental modeling (CM), previously used for [¹¹C]thymidine, and a novel DI spectral analysis (SA) approach on the tracers 5-[¹⁸F]fluorouracil (5-[¹⁸F]FU) and [¹⁸F]fluorothymidine ([¹⁸F]FLT). CM and SA were performed initially with a SI approach using the parent plasma TAC as an input function. These methods were then employed using a DI approach with the metabolite plasma TAC as an additional input function. Regions of interest (ROIs) corresponding to healthy liver, kidneys and liver metastases for 5-[¹⁸F]FU and to tumor, vertebra and liver for [¹⁸F]FLT were analyzed. For 5-[¹⁸F]FU, the improvement of the fit quality with the DI approaches was remarkable; in CM, the Akaike information criterion (AIC) always selected the DI over the SI model. Volume of distribution estimates obtained with DI CM and DI SA were in excellent agreement, for both parent 5-[¹⁸F]FU (R(2) = 0.91) and metabolite [¹⁸F]FBAL (R(2) = 0.99). For [¹⁸F]FLT, the DI methods provided notable improvements but less substantial than for 5-[¹⁸F]FU due to the lower rate of metabolism of [¹⁸F]FLT. On the basis of the AIC values, agreement between [¹⁸F]FLT K(i) estimated with the SI and DI models was good (R² = 0.75) for the ROIs where the metabolite contribution was negligible, indicating that the additional input did not bias the parent tracer only-related estimates. When the AIC suggested a substantial contribution of the metabolite [¹⁸F]FLT-glucuronide, on the other hand, the change in the parent tracer only-related parameters was significant (R² = 0.33 for K(i)). Our results indicated that improvements of DI over SI approaches can range from moderate to substantial and are more significant for tracers with a high rate of metabolism. Furthermore, they showed that SA is suitable for DI modeling and can be used effectively in the analysis of PET data.

[1]  F. O’Sullivan,et al.  Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: preliminary patient results. , 2002, Molecular imaging.

[2]  N. Sadato,et al.  Noninvasive measurement of cerebral metabolic rate of glucose using standardized input function. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  Scott T. Grafton,et al.  Kinetics and Modeling of l-6-[18F]Fluoro-DOPA in Human Positron Emission Tomographic Studies , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[4]  T. Jones,et al.  Spectral Analysis of Dynamic PET Studies , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  S. Osman,et al.  Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action , 2000, The Lancet.

[6]  J. Seibyl,et al.  Graphical analysis and simplified quantification of striatal and extrastriatal dopamine D2 receptor binding with [123I]epidepride SPECT. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  D. Mankoff,et al.  Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: compartmental model and mathematical analysis. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  F. O’Sullivan,et al.  Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: compartmental model investigation and mathematical analysis. , 2002, Molecular imaging.

[9]  D. Mankoff,et al.  A graphical analysis method to estimate blood-to-tissue transfer constants for tracers with labeled metabolites. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  David P. Chynoweth,et al.  Kinetics and modeling. , 1987 .

[11]  Mark Muzi,et al.  Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  W. J. Lorenz,et al.  Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. , 1997, Cancer research.

[13]  Alessandra Bertoldo,et al.  Voxel-Based Estimation of Kinetic Model Parameters of the l-[1-11C]Leucine PET Method for Determination of Regional Rates of Cerebral Protein Synthesis: Validation and Comparison with Region-of-Interest-Based Methods , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[14]  J. Bading,et al.  Kinetic modeling of 5-fluorouracil anabolism in colorectal adenocarcinoma: a positron emission tomography study in rats. , 2003, Cancer research.

[15]  S. Gunn,et al.  Positron Emission Tomography Compartmental Models , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[16]  Yukito Shinohara,et al.  Quantitative PET cerebral glucose metabolism estimates using a single non-arterialized venous-blood sample , 2004, Annals of nuclear medicine.

[17]  L. Bass,et al.  Liver kinetics of glucose analogs measured in pigs by PET: importance of dual-input blood sampling. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  S. Shousha,et al.  Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. , 2005, Cancer research.

[19]  R K Jain,et al.  Transport of molecules, particles, and cells in solid tumors. , 1999, Annual review of biomedical engineering.

[20]  F. Turkheimer,et al.  Kinetic filtering of [18F]Fluorothymidine in positron emission tomography studies , 2010, Physics in medicine and biology.

[21]  F. Turkheimer,et al.  The Use of Spectral Analysis to Determine Regional Cerebral Glucose Utilization with Positron Emission Tomography and [18F]Fluorodeoxyglucose: Theory, Implementation, and Optimization Procedures , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  F. Turkheimer,et al.  On the Undecidability among Kinetic Models: From Model Selection to Model Averaging , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  I. Buvat,et al.  A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology , 2012, Physics in medicine and biology.

[24]  A general method to correct PET data for tissue metabolites using a dual-scan approach. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  Eric O. Aboagye,et al.  Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  Janet F. Eary,et al.  Kinetic Analysis of 2-[11C]Thymidine PET Imaging Studies of Malignant Brain Tumors: Preliminary Patient Results , 2002 .

[27]  Dong Soo Lee,et al.  Kinetic Modeling of 3′-Deoxy-3′-18F-Fluorothymidine for Quantitative Cell Proliferation Imaging in Subcutaneous Tumor Models in Mice , 2008, Journal of Nuclear Medicine.